These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 817221)

  • 1. The antiparkinsonian efficacy of bromocriptine.
    Lieberman A; Zolfaghari M; Boal D; Hassouri H; Vogel B; Battista A; Fuxe K; Goldstein M
    Neurology; 1976 May; 26(5):405-9. PubMed ID: 817221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine treatment in Parkinson's disease.
    Parkes JD; Marsden CD; Donaldson I; Galea-Debono A; Walters J; Kennedy G; Asselman P
    J Neurol Neurosurg Psychiatry; 1976 Feb; 39(2):184-93. PubMed ID: 772175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
    Rascol A; Montastruc JL; Rascol O; Senard JM
    Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK
    Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists.
    Goldstein M; Engel J; Lieberman A; Regev I; Bystritsky A; Mino S
    J Neural Transm Suppl; 1983; 18():257-63. PubMed ID: 6135744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E; Hubener K; Fischer PA
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease with lergotrile mesylate.
    Lieberman A; Estey E; Kupersmith M; Gopinathan G; Goldstein M
    JAMA; 1977 Nov; 238(22):2380-2. PubMed ID: 335094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism.
    Kartzinel R; Shoulson I; Calne DB
    Neurology; 1976 Jun; 26(6 PT 1):511-3. PubMed ID: 778655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M; Lieberman A; Battista AF; Lew JY; Hata F
    Pharmacology; 1978; 16 Suppl 1():143-9. PubMed ID: 25445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
    Lieberman AN; Neophytides A; Leibowitz M; Gopinathan G; Pact V; Walker R; Goodgold A; Goldstein M
    Adv Neurol; 1983; 37():95-108. PubMed ID: 6858782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF; Bergsrud D; Elton RL; Racy A
    Clin Neuropharmacol; 1986; 9(2):138-45. PubMed ID: 3708599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
    Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experiences with a new ergoline (CF 25-397) in parkinsonism.
    Teychenne PF; Pfeiffer R; Bern SM; Calne DB
    Neurology; 1977 Dec; 27(12):1140-3. PubMed ID: 563012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
    Rascol O; Fabre N; Teräväinen H; Poewe W; Lücking C; Rinne U; Dupont E; Hirt D; Hoyer M; Lataste X
    Clin Neuropharmacol; 1990 Aug; 13(4):303-11. PubMed ID: 2208182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lergotrile in Parkinson disease: further studies.
    Lieberman AN; Gopinathan G; Estey E; Kupersmith M; Goodgold A; Goldstein M
    Neurology; 1979 Feb; 29(2):267-72. PubMed ID: 34808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.